Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1084 plus pembrolizumab versus pembrolizumab plus platinum-doublet chemotherapy in first-line KRAS G12C-mutant advanced nonsquamous NSCLC
NL-OMON60328Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing MK-1084 + pembrolizumab with Pembrolizumab + platinum-doublet chemotherapy (2 arms). Primary endpoint: Progression-free survival in participants with PD-L1 TPS at least 1%. Started Apr 2026; status: recruiting.
02
Drugs
calderasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60328.